title: Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.
abstract: Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i-induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i-induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles.
authors.affiliation: Institut de recherches cliniques de Montréal, Montreal, QC.
authors.forename: P
authors.initials: P
authors.lastname: Larochelle
authors.forename: C
authors.initials: C
authors.lastname: Kollmannsberger
authors.forename: R D
authors.initials: RD
authors.lastname: Feldman
authors.forename: E L
authors.initials: EL
authors.lastname: Schiffrin
authors.forename: L
authors.initials: L
authors.lastname: Poirier
authors.forename: F
authors.initials: F
authors.lastname: Patenaude
authors.forename: D
authors.initials: D
authors.lastname: Ruether
authors.forename: M
authors.initials: M
authors.lastname: Myers
authors.forename: G
authors.initials: G
authors.lastname: Bjarnason